A primer-probe composition, kit, and application for HLA allele typing

By using single-tube multiplex fluorescent PCR technology and specific primer-probe combinations, the problems of cumbersome HLA-B51 detection procedures and high false positive rates have been solved, achieving efficient and accurate HLA-B51 allele typing, which is suitable for assessing the genetic risk of Behçet's disease.

CN123108141APending Publication Date: 2026-11-17WENZHOU PUXI MEDICAL LAB CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202611595992.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-15
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing HLA-B51 detection technologies suffer from problems such as cumbersome detection procedures, large sample consumption, high false positive rates, and high false negative rates. Furthermore, existing fluorescent PCR technologies face challenges such as primer dimer formation, fluorescence spectrum crosstalk, amplification bias, and inhibitor interference, making it difficult to achieve efficient and accurate HLA-B51 allele typing.

Method used

A single-tube multiplex fluorescent PCR system was used, employing a specific primer and probe composition to target three core SNP sites of the HLA-B51 allele. The results were interpreted using a three-channel combination of FAM, ROX, and HEX, and the hot-start Taq enzyme was blocked with an antibody to ensure amplification synchronicity and signal accuracy.

Benefits of technology

It achieves high specificity and high sensitivity in HLA-B51 allele typing, shortens the detection time, reduces the amount of samples used, and lowers the false positive rate, making it suitable for large-scale clinical sample typing screening.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123108141A_ABST
    Figure CN123108141A_ABST
Patent Text Reader

Abstract

This invention, entitled "A Primer-Probe Composition, Kit, and Application for HLA Allele Typing," belongs to the fields of molecular biology and gene technology. The technical problem it aims to solve is to overcome the shortcomings of existing HLA-B51 genotyping methods, such as cumbersome operation, susceptibility to false positives from homologous subtypes, difficulty in result interpretation, and susceptibility to contamination during the detection process. The invention provides a primer-probe composition for HLA-B51 allele genotyping. The key technical points are that the three probes in the primer-probe composition are labeled with three different fluorescent groups: FAM, ROX, and HEX. A positive signal must be detected simultaneously in all three fluorescence channels (FAM, ROX, and HEX) for the sample to be considered to carry the HLA-B51 allele. This significantly reduces false positives caused by homologous sequences, provides high detection sensitivity, is easy to operate, and is suitable for batch sample genotyping.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of molecular biology and gene technology, specifically to a primer-probe composition, kit, and application for HLA allele typing. Background Technology

[0002] Behçet's disease is highly associated with the HLA-B51 allele, and HLA-B51 allele typing results can provide genetic reference for the auxiliary diagnosis and risk assessment of Behçet's disease. Most existing HLA-B51 detection methods employ a combination of conventional PCR amplification and Sanger sequencing. This requires separate amplification of the target gene and internal reference gene, purification of the PCR products, and subsequent sequencing. The process is lengthy, involves numerous steps, consumes a large amount of sample, and suffers from the risk of peak overlap during sequencing interpretation, demanding a high level of expertise from the operators.

[0003] The HLA-B gene family has a large number of alleles, and subtypes share high sequence homology, with some subtypes differing only by a few bases. This makes them highly susceptible to nonspecific amplification, leading to false positive results. If fluorescent PCR is used for HLA-B51 detection, it is first necessary to screen and identify specific SNP sites. Multiple sets of specific probes should then be designed for these SNP sites. Only when all these SNP sites are detected simultaneously can the sample be confirmed to carry the HLA-B51 allele. Fluorescent PCR technology is simple to operate, taking only 2 hours from sampling to results. However, it also faces two technical challenges: 1) The HLA-B gene family has a vast number of alleles, currently at least 6,000 sequences, and subtypes share high sequence homology, requiring bioinformatics software for data comparison to screen SNP sites and confirmation using clinical samples; 2) The multi-color fluorescent multiplex amplification system in a single tube has inherent technical difficulties: primer dimers easily form between different primer-probe sets, and probes hybridize; different target fragments exhibit amplification efficiencies with biases, resulting in uneven signal intensity across fluorescent channels; spectral crosstalk easily occurs between fluorescent groups, interfering with signal interpretation; and the presence of inhibitors such as hemoglobin and polysaccharides in genomic samples can easily cause signal loss in some channels, leading to false negatives. Current technologies do not publicly disclose an integrated multiplex amplification system adapted to the aforementioned multi-channel joint interpretation mode, making it difficult to balance detection specificity, sensitivity, and anti-interference capabilities.

[0004] Relevant patent documents retrieved: This document, published in China (CN105177152A) on December 23, 2015, discloses a method and primers for detecting the HLA-B51 allele. The primers include forward and reverse primers covering the HLA-B51 allele sequence, an internal control primer, and sequencing primers. Based on Sanger sequencing, these sequencing primers can be used for rapid and accurate detection of the HLA-B51 allele, and can be applied to studies on the association between HLA-B51 and Behçet's disease.

[0005] This document, published in China (CN119662798A) on March 21, 2025, discloses a primer set, kit, and method for high-resolution genotyping of 11 human leukocyte antigen (HLA) loci using nanopore sequencing technology. The primer set for HLA high-resolution genotyping includes primer pairs for HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DRB3 / 4 / 5, HLA-DQA1, HLA-DQB1, HLA-DPA1, and HLA-DPB1 loci. The primer set for multiplex amplification of 11 genes used in this paper for HLA genotyping enables simultaneous amplification of HLA genes HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DQA1, HLA-DQB1, HLA-DPA1, and HLA-DPB1 sites in a single reaction system. This improves the integrity, efficiency, and uniformity of gene amplification, as well as the accuracy of subsequent HLA genotyping.

[0006] This document, published in China (CN116334142A) on June 27, 2023, discloses compositions and methods for increasing the immunocompatibility of donor cells (e.g., HSCs or T cells) for transplantation into recipient subjects, as well as a database pattern for use in the methods. The methods and compositions described in this document produce allelic-specific modifications to one or more immunogenic genes (e.g., HLA genes) of the cells, thereby producing cells suitable for transplantation into recipient subjects.

[0007] The document, published in China (CN119864090A) on April 22, 2025, discloses a method for preparing personalized cancer vaccines and a method for training a machine learning HLA-peptide presentation prediction model.

[0008] Relevant non-patent literature retrieved: The journal title is *Chinese Journal of Microbiology and Immunology*, the article title is "Comparison of the Effects of Three Operating Systems for HLA Genotyping", Volume 23, Publication Date is January 30, 2003. This article discloses that RSSO uses site-specific primers to amplify DNA fragments encoding one or more exons. Specific alleles are immobilized on dot-matrix or linear hybridization membranes with corresponding oligonucleotide probes. The number of probes varies from 30 to 70, enabling RSSO to achieve allele recognition. Then, the genomic amplification products are reverse hybridized with the oligonucleotide probes immobilized on the nylon membrane, and after rigorous membrane washing, they are subjected to biotinylate or fluorescent chemical reactions.

[0009] The prior art represented by the aforementioned documents has at least the following unresolved technical problems or defects: The patent, published under CN105177152A, describes a method that involves PCR amplification followed by Sanger sequencing of the PCR products. The sequencing data is then compared with a template to confirm the final result. This method is cumbersome, requiring identification, sequencing, and data interpretation of the PCR products, and takes at least two days to obtain results.

[0010] The patent, published under CN119662798A, describes a primer set, kit, and genotyping method for accurately identifying 11 loci of human leukocyte antigen (HLA) at ultra-high resolution using nanopore sequencing technology. This method requires long-range PCR amplification, followed by library construction, which is time-consuming. Subsequent nanopore sequencing and bioinformatics analysis of the sequencing data using specialized software are also required. The entire process is cumbersome, highly specialized, and costly, making it unsuitable for widespread adoption and use. Summary of the Invention

[0011] The purpose of this invention is to provide: A primer-probe composition for HLA allele typing, and related technologies thereof, to address technical issues such as improving HLA-B51 typing specificity, shortening detection time, and reducing sample volume, or a combination thereof.

[0012] Terminology Explanation: Unless otherwise defined, all technical terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this subject matter pertains. Unless otherwise stated, all patents, patent inventions, and disclosures cited throughout this document are incorporated herein by reference in their entirety. Where multiple definitions exist for terms herein, the definitions provided in this chapter shall prevail.

[0013] It should be understood that the above brief description and the following detailed description are exemplary and for illustrative purposes only, and do not limit the subject matter of the invention in any way. In this invention, the singular is used in conjunction with the plural unless otherwise specifically stated. It should also be noted that, unless otherwise stated, the use of “or” or “or” means “and / or”. Furthermore, the use of the term “comprising” and other forms such as “including,” “containing,” and “contains” are not limiting.

[0014] Definitions of standard terms can be found in the references Microbiology (Science Press, 1985, Edition 2), Fundamentals of Clinical Laboratory Testing (Science Press, 2022-10, Edition 2), Clinical Molecular Biology Testing Techniques (Huazhong University of Science and Technology Press, 2020-01), and Compilation of Technical Review Guidelines for Registration of In Vitro Diagnostic Reagents (Zhengzhou University Press, 2019-09).

[0015] Unless otherwise stated, conventional methods within the scope of the art, such as ultraviolet spectrophotometry, real-time fluorescent PCR amplification and fluorescence signal acquisition, and Sanger sequencing verification, shall be used.

[0016] Unless specifically defined herein, the use of all commercially available products herein employs standard techniques. For example, it may be carried out using the manufacturer's instructions for use with the kit, or in accordance with methods known in the art or the description of this invention. The techniques and methods described herein can generally be implemented according to conventional methods well known in the art, based on the descriptions in the various summary and more specific documents cited and discussed in this specification.

[0017] The “range” disclosed in this document takes the form of a lower limit and an upper limit. It can be one or more lower limits and one or more upper limits, respectively. A given range is defined by selecting a lower limit and an upper limit. The selected lower and upper limits define the boundaries of the particular range. All ranges that can be defined in this way are inclusive and composable; that is, any lower limit can be combined with any upper limit to form a range. For example, if ranges of 60-120 and 80-110 are listed for a specific parameter, it is also expected that ranges of 60-110 and 80-120 are also expected. Furthermore, if the minimum range values ​​are listed as 1 and 2, and if the maximum ranges are listed as 3, 4, and 5, then the following ranges are all expected: 1-2, 1-4, 1-5, 2-3, 2-4, and 2-5.

[0018] In this invention, unless otherwise specified, the numerical range "ab" represents a shortened representation of any combination of real numbers from a to b, where a and b are both real numbers. For example, the numerical range "0-5" means that all real numbers between "0-5" have been listed in this document, and "0-5" is simply a shortened representation of these numerical combinations.

[0019] The term "primer" as used in this article refers to a short nucleic acid sequence (usually DNA or RNA), typically 15-30 nucleotides in length, which plays a crucial role as the starting point for nucleic acid synthesis in molecular biology techniques. Its core function is to provide DNA polymerase with the 3-OH terminus for initiating synthesis, guiding the enzyme to extend new nucleic acid chains along the template strand.

[0020] The term "upstream primer" as used in this article refers to a short oligonucleotide sequence that binds complementary to the non-coding strand (antisense strand) of the target DNA template in the PCR reaction, located at the 5' end of the target region. Its function is to guide DNA polymerase to synthesize a new DNA strand from the 5'-3' direction, starting at the upstream boundary of the target region.

[0021] The term "probe" as used in this article refers to a labeled single-stranded nucleic acid (DNA or RNA) or antibody molecule used to specifically identify and detect target molecules (such as nucleic acid sequences, proteins, cell structures, etc.) in a sample.

[0022] The term "PCR" used in this article refers to polymerase chain reaction, a technique for amplifying specific DNA fragments in vitro. It achieves exponential amplification of DNA fragments through a cycle of high-temperature denaturation, low-temperature annealing, and temperature-appropriate extension.

[0023] As used in this article, "amplification" refers to the process of significantly increasing the copy number of a specific nucleic acid fragment through biotechnology. In molecular biology, the most common amplification method is PCR, but other techniques are also included (such as rolling circle amplification, NASBA, etc.).

[0024] As used in this article, the term "reagent kit" refers to a standardized product that combines various experimental materials and reagents for specific detection, analysis, or experimental procedures. This includes: molecular biology reagent kits (such as PCR kits), immunoassay kits (such as ELISA kits), and clinical diagnostic kits (such as COVID-19 nucleic acid test kits).

[0025] The term "fluorescent group" as used herein refers to a chemical group capable of absorbing the energy of excitation light of a specific wavelength and emitting a longer wavelength fluorescence signal. In this application, it is used to label vesicles, peptides, or nucleic acid molecules to achieve tracing, localization, and quantitative detection through fluorescence signals.

[0026] The term "quenching group" used in this article refers to a chemical group that can absorb the fluorescence energy emitted by a fluorescent group through energy transfer and other means, thereby inhibiting the fluorescent signal produced by the fluorescent group. When the spatial distance between the fluorescent group and the quenching group changes, the fluorescence signal can be recovered, and it is often used to construct responsive probes.

[0027] The term "Tm" used in this article refers to the nucleic acid melting temperature, which represents the temperature at which 50% of a double-stranded nucleic acid molecule melts and dissociates into a single-stranded nucleic acid. The unit is degrees Celsius (°C), and it is used to guide the design of PCR primers and probes and the setting of amplification annealing temperature parameters.

[0028] In a first aspect, the present invention provides a primer-probe composition for HLA allele typing, the primer-probe composition comprising three sets of primer-probe pairs.

[0029] Specifically, the first primer-probe pair consists of forward primer B51-687TF1 (SEQ ID NO:1), reverse primer B51-687TR2 (SEQ ID NO:2), and probe B51-687TP1 (SEQ ID NO:3). The second primer-probe pair consists of forward primer B51-846AF1 (SEQ ID NO:4), reverse primer B51-846AR1 (SEQ ID NO:5), and probe B51-846AP1 (SEQ ID NO:6). The third primer-probe pair consists of forward primer B51-1251TF1 (SEQ ID NO:7), reverse primer B51-1251TR1 (SEQ ID NO:8), and probe B51-1251TP1 (SEQ ID NO:9). Furthermore, in the primer-probe composition, the Tm difference between each group of primers and probes is ≤2.5℃.

[0030] The probe may be labeled with a fluorescent group or a quencher group at its 5' end or 3' end; Specifically, the fluorescent group is selected from at least one of FAM, HEX, and ROX; The quenching group is selected from at least one of BHQ1, BHQ2, and BHQ1; More specifically, probe B51-687TP1 (SEQ ID NO:3) is labeled with the FAM fluorescent group, probe B51-846AP1 (SEQ ID NO:6) is labeled with the HEX fluorescent group, and probe B51-1251TP1 (SEQ ID NO:9) is labeled with the ROX fluorescent group.

[0031] More specifically, the probe Tm value for FAM-BHQ1 is 65.5-67.5℃; the probe Tm value for ROX-BHQ2 is 71-73℃; and the probe Tm value for HEX-BHQ1 is 55-57℃.

[0032] In some specific embodiments, the primer-probe composition is used for single-tube multiplex fluorescent PCR detection; during detection, the sample is determined to carry the HLA-B51 allele only when the three fluorescent channels FAM, ROX, and HEX simultaneously detect positive signals.

[0033] In some specific embodiments, the primer-probe composition targets three core SNP sites of the HLA-B51 allele; Specifically, the gene coordinates of the three core SNP loci are hg38, chr6 31356759 A>T; chr6 31356708 A>T; chr6 31271372 G>T; The recognition regions of the three sets of probes in the primer-probe composition cover all three core SNP sites.

[0034] In the primer-probe composition, the final concentration of each set of upstream and downstream primers is independently 0.10-0.35 μM, for example 0.10 μM, 0.14 μM, 0.18 μM, 0.20 μM, 0.24 μM, 0.30 μM, 0.35 μM, or any range derived therefrom; More preferably, the final concentration of each set of upstream and downstream primers is independently 0.18-0.24 μM; In the primer-probe composition, the final concentration of each fluorescent probe is independently 0.08-0.25 μM, for example 0.08 μM, 0.10 μM, 0.12 μM, 0.15 μM, 0.18 μM, 0.22 μM, 0.25 μM, or any range derived therefrom; More preferably, the final concentration of each fluorescent probe is independently 0.12-0.18 μM; The Tm difference between each group of primers and probes is ≤2.5℃.

[0035] The sequences of the primers and probes are as follows: Table 1.

[0036] Secondly, the present invention provides the application of the above-mentioned primer and probe composition in the preparation of an HLA-B51 allele typing single-tube multiplex fluorescent PCR detection kit.

[0037] Thirdly, the present invention provides a kit for detecting the HLA-B51 allele for non-diagnostic and therapeutic purposes, the kit containing the primer and probe composition described above.

[0038] In some specific embodiments, the kit also includes PCR reaction solution, HLA-B51 positive control, and negative control; Preferably, the PCR reaction solution comprises PCR buffer, DNA polymerase, dNTPs, dUTP enzyme, MgCl2, and nuclease-free water; More preferably, the PCR buffer is a Tris-HCl buffer system, wherein the concentration of Tris-HCl is 15-40 mM; More preferably, the PCR buffer is a Tris-HCl buffer system with a concentration of 25 mM; More preferably, the pH of the PCR buffer is 8.2-8.8, for example 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, or any range derived therefrom; More preferably, the pH of the PCR buffer is 8.4.

[0039] Preferably, the hot-start DNA polymerase is selected from at least one of antibody-blocked hot-start Taq DNA polymerase and chemically modified hot-start Taq DNA polymerase; More preferably, the hot-start DNA polymerase is an antibody-blocked hot-start Taq DNA polymerase; More preferably, the amount of hot-start DNA polymerase used is 0.8-2.0 U / 20 μL reaction system, such as 0.8 U, 1.0 U, 1.2 U, 1.5 U, 1.8 U, 2.0 U, or any range derived therefrom; Most preferably, the amount of hot-start DNA polymerase used is 1.2-1.5 U / 20 μL reaction system. Preferably, the positive control is a recombinant plasmid containing three core SNP sites of the HLA-B51 allele. Preferably, the negative control is physiological saline.

[0040] In some specific embodiments, the reagent kit detection method includes the following steps: S1. Extract nucleic acid from the sample to be tested; S2. Prepare a PCR reaction solution containing the primer and probe set; S3, PCR amplification, and continuous melting curve acquisition; S4. Based on the joint interpretation of FAM, ROX and HEX three-channel signals, determine whether the sample carries the HLA-B51 allele.

[0041] In some specific implementations, the PCR amplification-melting procedure conditions detected by the kit are as follows: Step 1: 37℃, 2 minutes; Step 2: 95℃, 2 minutes; Step 3: 95℃, 10s; 58℃, 20s; 72℃, 20s; cycle 45 times; collect FAM, ROX, and HEX fluorescence at 58℃ for 20s; Step 4: 95℃, 1 min; 45℃, 5 min; Step 5: Continuous melting and scanning at a heating rate of 0.05℃ / s from 45-90℃ to acquire FAM, ROX, and HEX fluorescence signals.

[0042] Results interpretation criteria: The sample is considered to carry the HLA-B51 allele only if all three fluorescence channels (FAM, ROX, and HEX) show a positive signal simultaneously; if any one fluorescence channel shows no positive signal, the sample is considered not to carry the HLA-B51 allele; the validity of the interpretation is based on the positive control showing positive results in all three channels and the negative control showing negative results in all channels in the same batch of experiments.

[0043] Fourthly, the present invention provides the use of the above-described primer-probe composition or the above-described detection kit in the preparation of detection reagents to assist in assessing the risk of genetic susceptibility to Behçet's disease.

[0044] The beneficial effects of this invention are as follows: The present invention has at least the following beneficial effects: 1. Compared to existing technologies that require separate tube amplification, PCR product purification, and Sanger sequencing, this invention uses a single-tube FAM / HEX / ROX three-target complex fluorescent PCR system. All three channels must be positive simultaneously to determine HLA-B51 positivity. By using multi-channel joint verification, false positive results caused by non-specific amplification of HLA homologous subtypes are effectively avoided, significantly improving the specificity of HLA-B51 typing.

[0045] 2. The entire test is completed in a single tube, eliminating the need for multi-tube PCR and reducing the risk of contamination from opening the tube; the system has high sensitivity, and low-copy templates can still be stably amplified; the sequencing step is eliminated, shortening the test time and reducing the amount of sample used; the operation process is simple and suitable for large-scale HLA-B51 allele typing screening in clinical and research settings.

[0046] 3. Provide positive and negative controls to ensure the reliability of each experimental result. Attached Figure Description

[0047] Figure 1 This is an example image of a positive control sample from Example 1. Detailed Implementation

[0048] The following non-limiting embodiments are intended to enable those skilled in the art to gain a more comprehensive understanding of the present invention, but do not limit the invention in any way. The following content is merely an exemplary description of the scope of protection claimed by the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, and such changes should also fall within the scope of protection claimed by the present invention.

[0049] The present invention will be further described below by way of specific embodiments. Unless otherwise specified, all instruments, devices, equipment, reagents, products, etc., used in the embodiments of the present invention are obtained through conventional commercial means.

[0050] The specific raw material information is shown in the table below: Table 2. Raw Material Information

[0051] Example 1 provides a multiplex fluorescent PCR detection system for HLA-B51 allele typing (total reaction volume: 30 μL). 1. Preparation of primer-probe composition: First, the primer and probe composition is prepared, and its composition is shown below.

[0052] Table 3. Composition of the primer-probe mixture

[0053] The Tm difference between each group of primers and probes should be controlled to be ≤2.5℃; 2. Preparation of PCR reaction solution: Prepare the PCR reaction solution according to the composition in the table below, add it to the PCR reaction tube, vortex for a few seconds, centrifuge at 3000 rpm for a few seconds, and the prepared PCR reaction solution can be used within 1 hour at 4℃ or within 4 hours at -20℃.

[0054] Table 4. Composition of PCR reaction solution

[0055] 3. Amplification procedure: The multiplex fluorescent PCR procedure is as follows: Table 5. PCR amplification program

[0056] 4. Aliquoting of PCR reaction solution: The PCR reaction solution is aliquoted into PCR thin-walled reaction tubes at 25 μL per tube.

[0057] 5. Transfer the prepared PCR reaction tubes to the extraction room and add 5 μL of sample DNA, positive control, and negative control, respectively.

[0058] 6. Result determination: Gene detection result determination: After the PCR reaction is completed, the validity of the detection is first determined by internal standard quality control, and then the melting curve is analyzed. Based on the differences in melting point and shape of the melting peak, the detection of each target gene is completed.

[0059] Genotype determination can only be performed when the yin-yang control sample meets all three of the following conditions.

[0060] ① Negative control samples: No typical melting peaks were observed for any of the detection targets; ② Positive control samples: Each detection target showed two typical melting peaks (wild-type and mutant melting peaks). See [link to sample]. Figure 1 ; ③ Both of the above requirements must be met simultaneously in the same test; otherwise, the test will be considered invalid and must be repeated.

[0061] The genotypes of each locus were determined according to the table below.

[0062] Table 6. Genotyping at each locus

[0063] When all three sites are positive, it indicates that the sample carries the HLA-B51 gene.

[0064] The Tm values ​​are common values ​​obtained on specific instruments and are used as a reference. When using other instruments, the Tm values ​​may vary slightly. The Tm values ​​obtained from the positive control of the current test shall prevail.

[0065] See the example image of the positive control sample. Figure 1 .

[0066] Comparative Example 1 Compared with Example 1, the only difference is that the probes in the first group are replaced with the probe sequence shown in SEQ ID NO.10, specifically the sequence information CGGAACACACAGATCTTCAAG (SEQ ID NO.10). All other conditions are basically the same as in Example 1.

[0067] Comparative Example 2 Compared with Example 1, the only difference is that the probes in the second group are replaced with the probe sequence shown in SEQ ID NO.11, specifically the sequence information CTGCGGATCGCGCTCCGCTACT (SEQ ID NO.11). All other conditions are basically the same as in Example 1.

[0068] Detection example 1. Accuracy Test (1) Experimental procedure: Twenty-five HLA-B51-positive clinical samples and 30 HLA-B51-negative clinical samples, confirmed by first-generation sequencing, were selected. Genomic DNA was extracted from all samples, and single-tube multiplex fluorescent PCR was performed using the primer and probe combinations and kits described in Example 1 and Comparative Examples 1-2, respectively. The PCR amplification-melting procedure followed the parameters described in Example 1. The FAM, ROX, and HEX signal interpretation results for each sample were recorded. The kit-based typing results were compared with the first-generation sequencing gold standard results, and a four-fold table was constructed to calculate the detection accuracy and concordance rate.

[0069] (2) The specific test data is shown below: Table 7. Accuracy Test Data

[0070] The data above shows that all 25 HLA-B51 sequencing positive samples were identified as positive by the kit in Example 1 of this invention, with positive signals detected simultaneously in all three channels; all 30 HLA-B51 sequencing negative samples were identified as negative by this kit, with no simultaneous positive results in all three channels; compared with the first-generation sequencing gold standard, the positive concordance rate was 100%, the negative concordance rate was 100%, and the overall concordance rate was 100%.

[0071] 2. Sensitivity Test (1) Experimental procedure: Take the HLA-B51 recombinant positive plasmid carrying the complete 3 core SNP loci, and perform serial dilutions with nuclease-free water to prepare plasmid concentrations of 10000 cp / μL, 1000 cp / μL, 100 cp / μL, 10 cp / μL, and 1 cp / μL; set up 3 replicates for each concentration; add to the PCR reaction system and execute the amplification-melting program (specific conditions are the same as in Example 1); record the Tm values ​​of the three fluorescence channels FAM, ROX, and HEX respectively, calculate the positive detection rate of each concentration, and determine the limit of detection (LOD) of the system in Example 1.

[0072] (2) Judgment criteria: Under the minimum detection limit concentration, all three channels can be stably detected, and the positive detection rate is ≥95%.

[0073] (3) The specific experimental results are shown below: Table 8. Sensitivity Test Data

[0074] The data above shows that the limit of detection (LOD) of the kit in Example 1 of this invention is 10 cp / μL. At a concentration of 10 cp / μL, all three parallel replicates of the FAM, ROX, and HEX channels can be stably detected, with a positive detection rate of 100%, meeting the ≥95% criterion. There is no stable detection at a template concentration of 1 cp / μL.

[0075] 3. Specificity test (1) Experimental procedure: Templates to be tested: 10 copies each of HLA-B07 and HLA-B08 homologous subtype plasmids, and 20 clinical negative genomic samples; HLA-B51 positive plasmid was set as a positive control, and template-free NTC system was set as a negative control; all samples were amplified using the single-tube multiplex fluorescent PCR system of Example 1 of this invention, and the amplification-melting procedure was performed (under the same conditions as in Example 1); the amplification signals and melting peaks of the three fluorescent channels FAM, ROX, and HEX were observed.

[0076] (2) Judgment criteria: Only the HLA-B51 positive control showed positive results in all three channels simultaneously; the HLA-B07, HLA-B08 and negative control groups showed no amplification signals in all three channels, with no false positives.

[0077] (3) Experimental results Positive control HLA-B51 plasmid: FAM, ROX, and HEX channels were all positive, with corresponding probe characteristic melting peaks appearing; 10 HLA-B07 subtype templates: at most only one channel showed a weak signal, and there was no simultaneous positivity in all three channels, so the interpretation result was negative; 10 HLA-B08 subtype templates: at most only two channels showed signals, and there was no simultaneous positivity in all three channels, so the interpretation result was negative; 20 clinical negative samples and NTC template-free controls: no obvious amplification signals were observed in FAM, ROX, and HEX channels, and there were no false positives.

[0078] The kit of this invention can effectively distinguish HLA-B51 from highly homologous subtypes of HLA-B07 and HLA-B08, with good specificity.

[0079] Verification of technical effectiveness and / or analysis of technical problem solving Experimental verification shows that this kit has a 100% overall concordance rate with the first-generation sequencing gold standard; a minimum detection limit of 10 cp / μL; it can effectively distinguish HLA-B51 from HLA-B07 and HLA-B08 homologous subtypes without false positives; the Ct difference of the three channels is less than 1.5, and the multiplex amplification is balanced, meeting the needs of clinical sample typing.

[0080] This invention addresses the problems of non-specific amplification, channel imbalance, and false positives that easily occur in multiplex PCR due to the high sequence similarity and high GC content of HLA-B51 and its homologous subtypes. It ensures synchronous amplification by controlling the Tm difference between primers to ≤2.5℃; reduces non-specific extension at room temperature by using antibody-blocked hot-start Taq enzyme; and combines FAM / ROX / HEX three-channel joint interpretation with melting curve dual verification.

[0081] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A primer-probe composition for HLA allele typing, characterized in that, The primer-probe composition comprises three primer-probe pairs; The first primer-probe pair consists of a forward primer with the nucleotide sequence shown in SEQ ID NO.1, a reverse primer with the nucleotide sequence shown in SEQ ID NO.2, and a probe with the nucleotide sequence shown in SEQ ID NO.

3. The second primer-probe pair consists of a forward primer with the nucleotide sequence shown in SEQ ID NO.4, a reverse primer with the nucleotide sequence shown in SEQ ID NO.5, and a probe with the nucleotide sequence shown in SEQ ID NO.

6. The third primer-probe pair consists of a forward primer with the nucleotide sequence shown in SEQ ID NO.7, a reverse primer with the nucleotide sequence shown in SEQ ID NO.8, and a probe with the nucleotide sequence shown in SEQ ID NO.

9.

2. The primer-probe composition according to claim 1, characterized in that, Each probe group has a fluorescent group labeled at its 5' end and a quenching group labeled at its 3' end; the fluorescent group is selected from at least one of FAM, HEX, and ROX; the quenching group is selected from at least one of BHQ1 and BHQ2.

3. The primer-probe composition according to claim 2, characterized in that, The probe Tm value for FAM-BHQ1 is 65.5-67.5℃; the probe Tm value for ROX-BHQ2 is 71-73℃; and the probe Tm value for HEX-BHQ1 is 55-57℃. The final concentration of each upstream and downstream primer in the primer-probe composition is independently 0.10-0.35 μM.

4. The primer-probe composition according to claim 1, characterized in that, The primer-probe composition targets three core SNP sites of the HLA-B51 allele, with gene coordinates of hg38, chr6 31356759 A>T; chr6 31356708 A>T; and chr6 31271372 G>T. The recognition regions of the three sets of probes in the primer-probe composition cover all three core SNP sites.

5. The primer-probe composition according to claim 1, characterized in that, The primer-probe composition is used for single-tube multiplex fluorescent PCR detection; during detection, the sample is determined to carry the HLA-B51 allele only when the three fluorescent channels FAM, ROX, and HEX show positive signals simultaneously.

6. The use of the primer and probe composition according to any one of claims 1-5 in the preparation of an HLA-B51 allele typing single-tube multiplex fluorescent PCR detection kit.

7. A kit for detecting the HLA-B51 allele for non-diagnostic and therapeutic purposes, characterized in that, The kit contains the primer and probe composition according to any one of claims 1-5.

8. The reagent kit according to claim 7, characterized in that, The kit also includes PCR reaction solution, HLA-B51 positive control, and negative control; The PCR reaction solution contains PCR buffer, DNA polymerase, dNTPs, dUTP enzyme, MgCl2, and nuclease-free water. The positive control is a recombinant plasmid containing the HLA-B51 allele containing three core SNP sites; the negative control is physiological saline.

9. The reagent kit according to claim 7, characterized in that, The PCR amplification-melting procedure for detection using the kit is as follows: Step 1: 95℃, 3 min, no fluorescence collection, perform 1 cycle; Step 2: Cyclic phase, 40 cycles in total: 95℃ for 15s, no fluorescence collection; 55℃ for 40s, fluorescence signal collection. Step 3: 90℃, 1 min, no fluorescence collection; 40℃, 3 min, no fluorescence collection, perform 1 cycle; Step 4: Melting curve scanning. The temperature is increased from 40℃ to 90℃ at a rate of 0.05℃ / s, and fluorescence signals are collected throughout the process. One cycle is performed.

10. The use of the primer-probe composition according to any one of claims 1-5 or the kit according to any one of claims 7-9 in the preparation of a diagnostic reagent to assist in assessing the risk of genetic susceptibility to Behçet's disease.

Citation Information

Patent Citations

  • Method and primers for detecting HLA-B*51 allelomorphic gene

    CN105177152A

  • Crispr / cas-related methods and compositions for improving transplantation

    CN116334142A

  • Genetic typing primer group for HLA (human leukocyte antigen) ultrahigh resolution level, kit and genetic typing method

    CN119662798A

  • Methods and systems for predicting HLA class II specific epitopes and characterizing CD4 + T cells

    CN119864090A